TETERBORO, N.J., and MOUNTAIN VIEW, Calif., Feb. 27 /PRNewswire/ --
Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider
of diagnostic laboratory testing, information and services, and Broadlane
Inc., a leader in delivering supply chain services to the healthcare industry,
today announced a long term agreement in which Quest Diagnostics will provide
a range of laboratory services to Broadlane's customer base of more than
500 acute care hospitals. Broadlane's customers include Tenet Healthcare
Corporation, Universal Health Services, Community Health Systems, IASIS
Healthcare, Cleveland Clinic Foundation, Kaiser Permanente and Continuum
Health Partners, Inc.
The agreement, effective January 1, 2001, establishes Quest Diagnostics as
the exclusive provider of diagnostic laboratory testing, information and
services to Broadlane. All eligible hospitals may access the agreement.
Previously, SmithKline Beecham Clinical Laboratories, which was acquired by
Quest Diagnostics in August 1999, had a reference testing agreement directly
with Tenet Healthcare Corporation.
"We are delighted to have this opportunity to continue to serve Broadlane
customers and look forward to expanding into new markets as Broadlane grows,"
said Surya N. Mohapatra, Ph.D., President and Chief Operating Officer for
Quest Diagnostics.
Under the agreement, Quest Diagnostics will offer a wide variety of
services to Broadlane's customers. As the exclusive provider for reference
laboratory testing services, Quest Diagnostics will provide world-class
testing, customer service, specimen collection and courier service, and
appropriate electronic interfaces to meet the needs of Broadlane's customers.
About Broadlane
Through an extensive suite of services, Broadlane delivers integrated
expense management solutions to the healthcare industry. Those services
include contracting, electronic commerce, expense management, data mining and
reporting, and complete responsibility for the materials management function.
Among the companies that focus on improving efficiencies within the healthcare
supply chain, only Broadlane offers materials management services, innovative
e-commerce technologies and integral group purchasing organization services to
best meet the needs of its customers.
Formed in December 1999, Broadlane's customers include Tenet Healthcare
Corporation, Universal Health Services, Community Health Systems, IASIS
Healthcare, the Cleveland Clinic Foundation, Kaiser Permanente and Continuum
Health Partners, Inc. Broadlane has offices in San Francisco, Calif., and
Dallas, Texas. For more information visit http://www.broadlane.com
About Quest Diagnostics
Quest Diagnostics is the nation's leading provider of diagnostic testing,
information and services with $3.4 billion in annual revenues. The company's
diagnostic testing yields information that enables health care professionals
and consumers to make better decisions to improve health. Quest Diagnostics
offers patients and physicians the broadest access to diagnostic testing
services through its national network of approximately 30 full-service
laboratories, 150 rapid response laboratories and 1,300 patient service
centers, where specimens are collected. Quest Diagnostics is the leading
provider of esoteric testing, including gene-based testing, and is the leader
in routine medical testing, drugs of abuse testing, and anatomic pathology
testing. Through partnerships with pharmaceutical, biotechnology and
information technology companies, Quest Diagnostics provides support to help
speed the development of health care insights and new therapeutics. Additional
company information can be found on the Internet at:
http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause the outcome to be
materially different. Certain of these risks and uncertainties are listed in
the Quest Diagnostics Incorporated 1999 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
CONTACT: Media - Gary Samuels, 201-393-5700,
samuelsg@questdiagnostics.com, or Investors - Cathy Doherty, 201-393-5030,
dohertyc@questdiagnostics.com, both of Quest Diagnostics Incorporated; or
David McAdam of Broadlane Media Relations, 650-903-5494,
david.mcadam@broadlane.com/